Generate Biomedicines (GENB) Q2 2026 earnings — TrendMatrix coverage

Reported EPS

-$0.52

Estimate

-$0.49

Surprise

-6.1%

Revenue (period 2026-06-30)

$6.3M

Score today

4.4/10

Revenue source: xbrl.

Generate Biomedicines (GENB) reported a wider loss than forecast — diluted EPS of -$0.52 against the -$0.49 estimate (a 6.1% shortfall).

TrendMatrix currently rates GENB Sell at 4.4/10; no pre/post engine snapshot brackets this report.

0 of the last 2 quarters beat the estimate; this quarter's -6.1% surprise compares with a -58.4% four-quarter average. Next scheduled report: 2026-11-05.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$16.66

Price target

$23.49

Stop

$15.24

Upside to target

+41.0%

Reward-to-risk

2.9:1

Model outputs from TrendMatrix’s engine as of 2026-09-05 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$2.10B

P/E (fwd)

-7.2

52-week range

$11.00–$22.67

Off 52-week high

26.5%

RSI (14)

53

Volume vs avg

0.51×

Score today

4.4/10